Persistent Asset Partners’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.35K Buy
+404
New +$18.8K ﹤0.01% 291
2025
Q4
Sell
-230
Closed -$108K 415
2025
Q3
$108K Sell
230
-45,252
-99% -$1.26M 0.07% 156
2025
Q2
$1.21M Buy
45,482
+45,252
+19,675% +$1.19M 0.89% 34
2025
Q1
$152K Sell
230
-38
-14% -$1.35K 0.13% 107
2024
Q4
$268 Buy
+268
New +$12.8K ﹤0.01% 141

Other funds holding MRNA

Persistent Asset Partners's MRNA Position: Q4 2025 in Review

Persistent Asset Partners sold out of Moderna (MRNA) in Q4 2025, closing a stake of 4,583 shares — an estimated $118K sold.

Persistent Asset Partners first reported a position in MRNA in Q3 2025 and held it in 1 quarter. The position peaked at $118K in Q3 2025. 672 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

  • Persistent Asset Partners reported no remaining Moderna position as of Q4 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 4,583 Moderna shares in Q4 2025, an estimated $118K.
  • Persistent Asset Partners first reported a position in Moderna in Q3 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Moderna position peaked at $118K in Q3 2025.
  • 672 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.